 |
 |
||
    |
 |
||
| Contact UsFAQsHelpful LinksSearch the SiteBusiness DevelopmentCareersHome |
|
Find the product you need: Latest News from Fougera 5.7.2009 Fougera Says New Study on Generic Drug Savings Is Proof that Industry 2.13.2009 Fougera Employees Celebrate 160th Anniversary [ more press releases ] |
 9.16.2005
FOUGERA® RECEIVES FIRST TENTATIVE GENERIC APPROVAL FOR METROGEL®
Melville, NY (September 16, 2005) -- Fougera, a specialty manufacturer of dermatologic and ophthalmic pharmaceuticals, announced today that it has received tentative FDA approval to introduce the first generic version of Metronidazole Topical Gel USP 0.75%. The patent on the branded product by Galderma expires on June 6, 2006. MetroGel® generated approximately $75 million in sales in 2004. It is indicated for the treatment of rosacea (see product package insert for full prescribing information). MetroGel® represents the eighth FDA approval and the third first-generic for Fougera thus far in 2005. “Our success in developing and marketing a consistent stream of topical products is gratifying. We continue to set the standard for bringing products our customers desire”, stated Dave Klaum, Sr. Vice President Commercial Operations. As a specialty pharmaceutical manufacturer of topical steroids, antibiotics and antifungal products, Fougera has received more topical generic FDA approvals than any other company during the past six years. This ability to provide a continuing stream of new products benefits both health care providers and patients seeking multi-source alternatives and reduced costs. For more information on Fougera’s complete line of topicals, or any other quality Fougera product, please call Fougera Customer Service at (800) 645-9833. Or visit the company online at www.fougera.com. Fougera is a leading manufacturer and distributor of a wide range of multi-source topical and ophthalmic pharmaceuticals, in both prescription and over-the-counter dosage forms. |
| Browse the Fougera Product Listing |
|